Entero Therapeutics, Inc. (ENTO) Financial Statements
Industry: Electric & Other Services Combined
In fiscal 2025, Entero Therapeutics reported revenue of $36,251. Net income was -$6.4M (a -17634.4% net margin), or -$4.16 per diluted share. Gross margin was -1813.6% and operating margin was -19540.0%. Operating activities generated -$5.7M of cash. At fiscal year end, Entero Therapeutics held $48.6M in total assets against $19.7M in total liabilities, including $899,784 of cash and equivalents.
Open the full interactive Entero Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Entero Therapeutics Key Stats
| Share Price | $4.55 |
|---|---|
| Market Cap | $29.2M |
| 52-Week Range | $2.01 – $6.80 |
| Shares Outstanding | 6.4 million (basic, 2026 Q2) |
Entero Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $36,251 |
| Gross Profit | — | — | — | — | — | -$657,432 |
| Operating Income | -$26.4M | -$59.1M | -$12.7M | -$15.8M | -$15.6M | -$7.1M |
| Pre-Tax Income | -$32.7M | -$58.5M | -$14.6M | -$15.8M | -$18.1M | -$6.6M |
| Income Tax | $0 | $0 | — | — | — | -$398,736 |
| Net Income | -$32.7M | -$58.5M | -$14.6M | -$15.8M | -$18.1M | -$6.4M |
| Diluted EPS | $3582972.79 | -$119322.00 | -$1260.00 | -$143.64 | -$15.99 | -$4.16 |
Entero Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $36,251 | $38,208 | $85,876 |
| Net Income | -$1.2M | -$3.0M | -$3.6M | -$12.8M |
| Diluted EPS | -$0.75 | -$1.84 | -$0.82 | -$2.01 |
Entero Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | $8.2M | $1.4M | $3.7M | $163,476 | $899,784 |
| Current Assets | $7.9M | $9.4M | $3.4M | $5.0M | $83.5M | $2.6M |
| Total Assets | $12.9M | $11.8M | $5.4M | $6.9M | $85.4M | $48.6M |
| Current Liabilities | $15.5M | $12.3M | $2.5M | $3.1M | $27.5M | $15.2M |
| Total Long-Term Debt | — | — | — | — | — | $2.0M |
| Total Liabilities | $15.6M | $19.6M | $2.7M | $3.3M | $27.6M | $19.7M |
| Shareholders' Equity | -$2.6M | -$7.8M | $2.7M | $3.6M | -$3.9M | $24.9M |
Entero Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$11.2M | -$32.3M | -$22.3M | -$12.4M | -$9.2M | -$5.7M |
| Cash From Investing | $87,350 | -$10.3M | — | -$500,000 | $88,169 | $323,482 |
| Cash From Financing | $17.0M | $44.8M | $15.7M | $15.2M | $5.6M | $5.9M |
| Free Cash Flow | -$11.2M | -$32.4M | -$22.4M | — | — | — |
Figures from Entero Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Entero Therapeutics financials page for every line item.
Entero Therapeutics Company Profile
| Ticker | ENTO |
|---|---|
| Exchange | Nasdaq |
| Industry | Electric & Other Services Combined |
| Headquarters | Boca Raton, Florida |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001604191 |
Frequently Asked Questions
What was Entero Therapeutics' revenue in fiscal 2025?
Entero Therapeutics (ENTO) reported revenue of $36,251 for fiscal 2025.
What is Entero Therapeutics' annual revenue history?
Entero Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $36,251.
What was Entero Therapeutics' net income in fiscal 2025?
Entero Therapeutics reported net income of -$6.4M for fiscal 2025.
What was Entero Therapeutics' earnings per share (EPS) in fiscal 2025?
Entero Therapeutics' diluted EPS was -$4.16 for fiscal 2025 (adjusted for any later stock splits).
What was Entero Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Entero Therapeutics reported revenue of $85,876.
How much debt does Entero Therapeutics have?
Entero Therapeutics reported $2.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Entero Therapeutics are outstanding?
Entero Therapeutics reported a weighted average of 6.4 million basic shares outstanding in 2026 Q2.
What is Entero Therapeutics' market cap?
Based on its latest closing price, Entero Therapeutics (ENTO) has a market capitalization of about $29.2M.
When does Entero Therapeutics' fiscal year end?
Entero Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Entero Therapeutics headquartered?
Entero Therapeutics lists its business address in Boca Raton, Florida in its SEC filings.